Predictors of retinopathy progression after HCQ discontinued? In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c Age - significant assoc'n with progression ✳️monitor toxicity more closely esp in older pts #ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ

• https://x.com/RHEUMarampa/status/1983262824530096270/photo/1

A new IA drug in OA 🚨 Cell therapy of apoptotic PBMCs ENX-CL-05-001 RCT Ph2A moderate to severe OA 134 pts 3 injections vs. PBO Pain improvement 24% Better response in people > 60 and more so 65yo Potential improvement for > 6mo Safety mainly local reactions to compound https://t.co/m2MZN3i22b

• https://x.com/AurelieRheumo/status/1983262445809311986/photo/1

Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr

• https://x.com/RHEUMarampa/status/1983260232655536303/photo/1

52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA Primary ACR 50 16wks Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW ACR50 50% 57% 51% ACR70 36% 42% 42% PASI100 55% 64% 58% MDA 47% 52% 47% No specific enthesitis data presented No new safety signal Next https://t.co/J18rSTmyze

• https://x.com/AurelieRheumo/status/1983258996652851292/photo/1

#1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients. Each rise in PM2.5 significantly boosted DAS28, CDAI & joint counts. Does cleaner air mean calmer joints? @RheumNow #ACR25

There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but that’s probably all the fraudulent hidden dexamethasone inside… Beware+++ #ACR25 FDA Update @RheumNow https://t.co/rco4wTXBjO

• https://x.com/drdavidliew/status/1983245491451376077/photo/1

US Electronic Health Record cohort 2000+pts Incidence Heart Failure over 10 yrs 6.8% HF asso w/ Older Male Lower eGFR Hypertensive medication Diabetes TTMTS MTX, TNFi Higher CRP Probably surrogates for High Disease Activity... How do we detect it? Maybe not by using the https://t.co/s9SjEyk3WF

• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1
• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1

@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile #ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB

• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1

Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa

• https://x.com/RichardPAConway/status/1983234558985417164/photo/1

#ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D

• https://x.com/Yuz6Yusof/status/1983232738934030504/photo/1

After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln

• https://x.com/drdavidliew/status/1983229116469162290/photo/1

#IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We

• https://x.com/Janetbirdope/status/1983227740267422026/photo/1
• https://x.com/Janetbirdope/status/1983227740267422026/photo/1

Adverse events from avacopan the WHO pharmacovigilence database (VigiBase) Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz

• https://x.com/EBRheum/status/1983225627403563379/photo/1

In the CLOSE-UP study of UPA in RA - 61% in remission with responses sustained to 24 mo - Benefit consistent irrespective of prior DMARD use - No new safety signals @RheumNow #ACR25 Abstract#2281

#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4

• https://x.com/Yuz6Yusof/status/1983220916264771657/photo/1